COMMENCE试验:RESILIA组织主动脉生物瓣2年结果
COMMENCE试验为前瞻性、多国、多中心、单臂FDA IDE研究,评估RESILIA组织主动脉瓣膜行外科主动脉瓣置换的安全性与有效性。
要点
- 2年全因死亡免除率94.3%,NYHA心功能改善者占65.7%。
- 2年瓣膜血流动力学稳定,平均压差10.1±4.3 mmHg。
核心结论
- RESILIA组织主动脉生物瓣行外科主动脉瓣置换显示出良好的早期安全性和有效性。
研究设计与样本
- 前瞻性、多国、多中心(n=27)、单臂、FDA研究性器械豁免试验。
- 2013年1月至2016年2月共689例患者接受Carpentier-Edwards PERIMOUNT Magna Ease主动脉瓣(RESILIA组织,型号11000A)。
主要发现
- 2年NYHA心功能改善者占65.7%,有效开口面积1.6±0.5 cm2,平均压差10.1±4.3 mmHg。
- 2年瓣周漏无/微量占94.5%,轻度4.9%,中度0.5%,重度0.0%。
- 孤立性AVR患者1年全因死亡免除率98.2%,2年95.3%;全部患者1年97.6%,2年94.3%。
临床怎么用
- 该瓣膜可用于有临床指征的外科主动脉瓣置换,早期结局支持其安全性。
- 术后2年血流动力学表现稳定,瓣周漏以无/微量为主。
局限性
- 单臂研究,无对照组,无法直接比较其他瓣膜。
- 随访时间为2年,缺乏长期耐久性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The COMMENCE trial was conducted to evaluate the safety and effectiveness of a novel bioprosthetic tissue for surgical aortic valve replacement (AVR). METHODS: Patients underwent clinically indicated surgical AVR with the Carpentier-Edwards PERIMOUNT™ Magna Ease™ aortic valve with RESILIA™ tissue (Model 11000A) in a prospective, multinational, multicentre (n = 27), single-arm, FDA Investigational Device Exemption trial. Events were adjudicated by an independent Clinical Events Committee; echocardiograms were analysed by an independent Core Laboratory. RESULTS: Between January 2013 and February 2016, 689 patients received the study valve. Mean age was 67.0 ± 11.6 years; 71.8% were male; 26.3% were New York Heart Association Class III/IV. Mean STS PROM was 2.0 ± 1.8 (0.3-17.5). Isolated AVR was performed in 59.1% of patients; others had additional concomitant procedures, usually CABG. Thirty-day outcomes for all patients included all-cause mortality 1.2%, thromboembolism 2.2%, bleeding 0.9%, major paravalvular leak 0.1% and permanent pacemaker implantation 4.7%. Median intensive care unit and hospital length of stay were 2 (range: 0.2-66) and 7 days (3.0-121.0), respectively. At 2 years, New York Heart Association class improved in 65.7%, effective orifice area was 1.6 ± 0.5 cm2; mean gradient was 10.1 ± 4.3 mmHg; and paravalvular leak was none/trivial in 94.5%, mild in 4.9%, moderate in 0.5% and severe in 0.0%. One-year actuarial freedom from all-cause mortality for isolated AVR and for all patients was 98.2% and 97.6%, respectively. Two-year actuarial freedom from mortality in these groups was 95.3% and 94.3%, respectively. CONCLUSIONS: These data demonstrate excellent early safety and effectiveness of aortic valve replacement with a novel bioprosthetic tissue (RESILIA™). CLINICAL TRIAL REGISTRATION: clinicaltrials.gov: NCT01757665.
引用
- Puskas JD, Bavaria JE, Svensson LG, et al. The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue. Eur J Cardiothorac Surg. 2017. PMID: 28605428. doi:10.1093/ejcts/ezx158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。